BioNTech SEBNTX +1.36%62 Quick Ratio is 8.74 as of Mar. 2026, which is 65% above its 10-year median of 5.30. GuruFocus rates BNTX with a GF Score™ of 62/100 and a GF Value™ of $89.10 (Fairly Valued). The stock has 5 warning signs investors should review. Among 1,413 Biotechnology companies, BioNTech SE ranks better than 74.52% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. BioNTech SE's quick ratio for the quarter that ended in Mar. 2026 was 8.74.
BioNTech SE has a quick ratio of 8.74. It generally indicates good short-term financial strength.
The historical rank and industry rank for BioNTech SE's Quick Ratio or its related term are showing as below:
BNTX'
s Quick Ratio Range Over the Past 10 Years
Min: 1.17 Med: 5.3 Max: 12.68
Current: 8.74
During the past 10 years, BioNTech SE's highest Quick Ratio was 12.68. The lowest was 1.17. And the median was 5.30.
BNTX's Quick Ratio is ranked better than 74.52% of 1413
companies
in the Biotechnology industry
Industry Median: 3.6
vs BNTX: 8.74
BioNTech SE (NAS:BNTX) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
BioNTech SE Quick Ratio Related Terms
BioNTech SE Quick Ratio Historical Data
* Premium members only.
The historical data trend for BioNTech SE's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BioNTech SE's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNTech SE Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioNTech SE's Quick Ratio distribution charts can be found below:
* The bar in red indicates where BioNTech SE's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
BioNTech SE's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioNTech SE (BNTX) has a Quick Ratio of 8.74 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on BioNTech SE and its competitors. This is 65% above median its historical median of 5.30. Over the past decade, BioNTech SE's Quick Ratio has ranged from 1.17 to 12.68. According to the industry distribution chart, BioNTech SE ranks #360 out of 1413 companies in the Biotechnology industry, placing it in the top 25.5%.
Is BioNTech SE's Quick Ratio too high?
BioNTech SE's current Quick Ratio of 8.74 is 65% above median its 10-year median of 5.30. Over the past 10 years, this metric has ranged from a low of 1.17 to a high of 12.68. The Biotechnology industry median Quick Ratio is 3.60. BioNTech SE's value of 8.74 is 142.8% above this industry median. Based on the distribution chart, BioNTech SE ranks #360 out of 1413 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BioNTech SE has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioNTech SE's Quick Ratio compare to RPRX and INSM?
According to the Biotechnology industry distribution chart, BioNTech SE ranks #360 out of 1413 companies for Quick Ratio. This puts BioNTech SE in the upper half of its industry. The industry median Quick Ratio is 3.60. BioNTech SE's value of 8.74 is 142.8% above this benchmark. Historically, BioNTech SE's own Quick Ratio has ranged from 1.17 to 12.68 over the past decade. While the company's 10-year median is 5.30 vs. the industry median of 3.60, BioNTech SE has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,413 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioNTech SE's current Quick Ratio of 8.74 is 142.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on BioNTech SE and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioNTech SE's current Quick Ratio is 8.74, which is 65% above median its own 10-year median of 5.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNTech SE stock overvalued right now?
Based on GuruFocus' analysis, BioNTech SE (BNTX) is currently considered Fairly Valued. The stock's GF Value™ is $89.10, compared to a current price of $91.22 — trading 2.4% above its estimated fair value. The current Quick Ratio is 8.74, which is 65% above median its 10-year median of 5.30 and 142.8% above the Biotechnology industry median of 3.60. BioNTech SE's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For BioNTech SE (BNTX), the current Quick Ratio is 8.74 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioNTech SE (BNTX) Overvalued in 2026?
Based on GuruFocus' analysis, BioNTech SE stock appears to be overvalued.
The current stock price of $91.22 is trading 2.4% above its estimated GF Value™ of $89.10.
GuruFocus considers BioNTech SE to be Fairly Valued.
Key valuation signals for BNTX:
Quick Ratio: 8.74 (65% above median its 10-year median of 5.30)
GF Value™: $89.10 vs. price of $91.22 (2.4% above fair value)
Industry Position: 142.8% above the Biotechnology median (#360 of 1413)
No single metric tells the full story. See the BNTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
62GF Score
Get the complete analysis for BNTX
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BNTX has been successfully added to your 
